Constitutive activation of NFκB in nuclear lysates from breast cancer cells has been observed [55], and it will be interesting to determine the responsible factors that contribute to NFκB pathway activation in EMT and claudin-low cells. Here, NFKB1 is linked to breast carcinoma.